The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma Eleonora BrunelloGiuseppe BoginaEmilio BriaMarco VergineGiuseppe Zamboni • Serena PedronIsabella DanieleJenny FurlanettoLuisa CarbogninMarcella Marconi • Erminia ManfrinMerdol IbrahimKeith MillerGiampaolo TortoraAnnamaria Molino • Bharat JasaniSerena BeccariFranco BonettiMarco ChilosiGuido MartignoniMatteo Brunelli

Eleonora Brunello,Giuseppe Zamboni,Serena Pedron,Isabella Daniele,Manfrin S. Beccari,Franco Bonetti,Marco Chilosi,Guido Martignoni,Matteo Brunelli,Giuseppe Bogina,Marcella Marconi,Emilio Bria,Jenny Furlanetto,Carbognin G. Tortora,Marco Vergine,Merdol Ibrahim,Keith W. Miller,Bharat Jasani

The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma Eleonora BrunelloGiuseppe BoginaEmilio BriaMarco VergineGiuseppe Zamboni • Serena PedronIsabella DanieleJenny FurlanettoLuisa CarbogninMarcella Marconi • Erminia ManfrinMerdol IbrahimKeith MillerGiampaolo TortoraAnnamaria Molino • Bharat JasaniSerena BeccariFranco BonettiMarco ChilosiGuido MartignoniMatteo Brunelli

2013

Purpose Triple (ER-, PR-, HER2-) negative breast carcinoma lack targeted therapies, making this group of tumors difficult to treat. By definition, the lack of HER2 expression means a case scoring 0 or 1? after immunophenotypical analysis and makes the patients avoiding therapeutical chances with anti-HER2 inhibitors. We sought to recruit from a group of triple negative breast carcinoma, patients eligible for effective personalized targeted therapy with anti-HER therapies on the basis of

Keywords:

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations